key: cord-0706327-mi6svas4
authors: Kamara, Rashidatu Fouad; Saunders, Matthew J; Sahr, Foday; Losa-Garcia, Juan E; Foray, Lynda; Davies, Geraint; Wingfield, Tom
title: Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study
date: 2022-03-15
journal: Lancet Glob Health
DOI: 10.1016/s2214-109x(22)00004-3
sha: b3bdfdaead8dee2204c0c3a0eb308f74aacce69b
doc_id: 706327
cord_uid: mi6svas4

BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) is a global health emergency. We aimed to evaluate treatment outcomes among people with MDR-TB in Sierra Leone and investigate social and health factors associated with adverse treatment outcomes. METHODS: This national, retrospective cohort study recruited all people notified with MDR-TB to the Sierra Leone National TB Programme, admitted to Lakka hospital (Lakka, Western Area Rural District, Freetown, Sierra Leone) between April, 2017, and September, 2019. Participants were followed up to May, 2021. People who were eligible but had no social or health data available, or were subsequently found to have been misdiagnosed, were excluded from participation. MDR-TB treatment was with the 2017 WHO-recommended short (9–11 month) or long (18–24 month) aminoglycoside-containing regimens. Multivariable logistic regression models examined associations of programmatic social and health data with WHO-defined adverse treatment outcomes (death, treatment failure, loss to follow-up). FINDINGS: Of 370 notified MDR-TB cases, 365 (99%) were eligible for study participation (five participants were excluded due to lack of social or health data or misdiagnosis). Treatment was started by 341 (93%) of 365 participants (317 received the short regimen, 24 received the long regimen, and 24 received no treatment). Median age was 35 years (IQR 26–45), 263 (72%) of 365 were male and 102 (28%) were female, 71 (19%) were HIV-positive, and 127 (35%) were severely underweight (body-mass index <16·5 kg/m(2)). Overall, 267 (73%) of 365 participants had treatment success, 95 (26%) had an adverse outcome, and three (1%) were still on treatment in May, 2021. Age 45–64 years (adjusted odds ratio [aOR] 2·4, 95% CI 1·2–5·0), severe underweight (aOR 4·2, 1·9–9·3), untreated HIV (aOR 10, 2·6–40·0), chronic lung disease (aOR 2·0, 1·0–4·2), previously unsuccessful drug-sensitive tuberculosis retreatment (aOR 4·3, 1·0–19), and a long regimen (aOR 6·5, 2·3–18·0) were associated with adverse outcomes. A sensitivity analysis showed that prothionamide resistance (aOR 3·1, 95% CI 1·5–10·0) and aminoglycoside-related complete deafness (aOR 6·6, 1·3–35) were independently associated with adverse outcomes. INTERPRETATION: MDR-TB treatment success in Sierra Leone approached WHO targets and the short regimen was associated with higher success. The social and health factors associated with adverse outcomes in this study suggest a role for integrated tuberculosis, HIV, and non-communicable disease services alongside nutritional and socioeconomic support for people with MDR-TB and emphasise the urgent need to scale up coverage of all-oral aminoglycoside-sparing regimens. FUNDING: Wellcome Trust, Joint Global Health Trials.

In line with our related research, we used an adapted version of WHO's medication adherence framework 1,2 to identify relevant baseline social and health variables that had a plausible or proven biological and epidemiological association with adverse treatment outcome and were collected by the NTP and available for analysis. These included age, sex, employment, incarceration, smoking history, BMI, comorbidities (HIV, diabetes, chronic kidney disease), chronic lung disease, severity of disease (defined by cavitating or miliary disease on chest radiograph), baseline smear positivity, and patient category (Box 1).

A patient who has completed treatment and has been had three consecutive negative cultures taken at least thirty days apart

A patient who has completed treatment, but does not meet the definition for cure due to lack of bacteriologic results (i.e. less than three negative cultures taken at least 30 days apart after the intensive phase)

The sum of cured and treatment completed 

*Of people with MDR-TB and untreated HIV who died, 8/14 (57%) received no treatment. Legend: Where variable data was incomplete, the category n value in parenthesis indicates the number of participants with complete data. TB case notifications and poverty levels are those in the district in which the patient was diagnosed before being referred to Lakka Hospital and are taken from nationally published data. Of the 24 patients who received long regimen, 4/24 (17%) were started on a short regimen but transferred to a long regimen during the same TB episode. A cell containing a hyphen indicates not applicable and in the case of chest radiograph findings this relates to multiple findings being possible in the same patient. Abbreviations: IQR = interquartile range; BMI = body mass index; CAT 1 = Category 1; CAT 2 = Category 2; PAS = para-aminosalicylic acid; LTFU = lost to follow up. Sputum smear, Xpert, culture and DST are all those at baseline. *362/365 people with MDR-TB had a recorded outcome because three people within the population cohort were still on treatment at the time of final analysis. **One participant in the cohort had a BMI >30 (obese) and was included in the BMI ≥25 (overweight) category ***These three participants with MDR-TB plus quinolone resistant were considered to have pre-XDR TB, there were no participants in this cohort with XDR-TB as defined by the 2016 WHO definition (i.e. MDR-TB plus resistance to any fluoroquinolone and at least one of amikacin, kanamycin, or capreomycin). 

Research protocol for a mixed-methods study to characterise and address the socioeconomic impact of accessing TB diagnosis and care in Nepal

Developing feasible, locally appropriate socioeconomic support for TBaffected households in Nepal

World Health Organization. Definitions and reporting framework for tuberculosis -2013 revision

Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin